Inovio Pharmaceuticals Inc (INO)

US · Healthcare · Biotechnology

$1.21+5.22%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Net profit

$-6.0M

EPS

$-0.07

EPS estimate

$-0.25

EPS came in at -0.07 against a street estimate of -0.25 — a beat of 72.0%.

Market cap

$136.5M

Forward P/E

16.6

P/B

33.35

Book value

$0.05

EPS (TTM)

$-1.03

52-week high

$2.72

52-week low

$0.56

50-day MA

$1.09

200-day MA

$1.42

Beta

1.63

Analysts rate Inovio Pharmaceuticals Inc a buy (3 buy, 2 hold, 0 sell out of 5) with an average price target of $3.17.

Insiders

0.33%

Institutions

46.01%

Fund	Stake
FMR Inc	9.03%
HHG PLC	3.20%
Vanguard Capital Management, LLC	2.81%
Boxer Capital Management, LLC	2.29%
ADAR1 Capital Management LLC	1.42%
D. E. Shaw & Co LP	1.31%
Eversept Partners, LP	1.00%
Geode Capital Management, LLC	0.78%

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Inovio Pharmaceuticals Inc — free to start.

Data updated 2026-09-18.